MDXG Q3 2023 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82M+20.7% YoY

Gross Profit

$67M81.9% margin

Operating Income

$11M13.6% margin

Net Income

$9M10.4% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+0.6%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$189M

Total Liabilities

$188M

Stockholders' Equity

$1M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$68M	+20.7%
Gross Profit	$67M	$56M	+20.6%
Operating Income	$11M	-$7M	+256.6%
Net Income	$9M	-$8M	+201.3%

Revenue Segments

Advanced Wound Care

$82M50%

Advanced Wound Care, Tissue And Other

$76M46%

Advanced Wound Care, Umbilical Cord-Derived

$6M4%

Product and Service, Other

$100,0000%

Section 351

$76,0000%